Dear Colleagues,

Globally, cervical cancer is the most commonly diagnosed gynecological cancer. With an estimated 570,000 cases and 311,000 deaths worldwide, cervical cancer is the fourth most commonly diagnosed cancer and the fourth leading cause of cancer-related death in women. Patients with locally advanced cervical cancer are primarily treated with concurrent cisplatin-based chemoradiotherapy. However, long-term progression-free survival and overall survival outcomes remain suboptimal, particularly for patients with larger tumors, lymph node metastases, and advanced disease.

In order to effectively treat cervical cancer, a multidisciplinary approach that includes surgery, radiotherapy, and systemic agents, is essential. Parallel to the innovations in treatment modalities, a rise in treatment efficacy and a decline in adverse events have been observed. In addition, radiotherapy increases the therapeutic efficacy of new systemic agents. Even in patients with recurrent or metastatic disease, the combined use of new generation systemic agents and new radiotherapy techniques is thought to improve survival.

This special edition will contain:
• A section describing the role of radiotherapy in the treatment of cervical cancer, as well as a section describing new treatment approaches;
• Original articles and (Systematic) Review articles with cervical cancer patients treated with radiotherapy, surgery, and/or systemic therapy; 
• A section on clinical perspectives, in which invited opinion leaders will provide their thoughts on the treatment of cervical cancer.

Prof. Dr. Cem Onal and Prof. Dr.  Guler Yavas
Guest Editors